Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion

Breast Cancer Research

Volumn 17, Issue 1, 2015, Pages

  Elsarraj, Hanan S ^a   Hong, Yan ^a   Valdez, Kelli E ^a   Michaels, Whitney ^a   Hook, Marcus ^a   Smith, William P ^a   Chien, Jeremy ^a   Herschkowitz, Jason I ^b   Troester, Melissa A ^c   Beck, Moriah ^d   Inciardi, Marc ^a   Gatewood, Jason ^a   May, Lisa ^e   Cusick, Therese ^e   McGinness, Marilee ^a   Ricci, Lawrence ^f   Fan, Fang ^a   Tawfik, Ossama ^a   Marks, Jeffrey R ^g   Knapp, Jennifer R ^h   Yeh, Hung Wen ^a   Thomas, Patricia ^a   Carrasco, D R ⁱ   Fields, Timothy A ^a   Godwin, Andrew K ^a   Behbod, Fariba ^a   more..

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d WICHITA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^f TRUMAN MEDICAL CENTER   (United States)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; SHORT HAIRPIN RNA; BCL9 PROTEIN, HUMAN; BETA CATENIN; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRANSCRIPTOME; TUMOR MARKER; TUMOR PROTEIN; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BCL9 GENE; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; EMBRYO; EPITHELIAL MESENCHYMAL TRANSITION; ERBB2 GENE; ESR1 GENE; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SILENCING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VIVO STUDY; INTRADUCTAL CARCINOMA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; RNA SEQUENCE; TUMOR GENE; TUMOR INVASION; UPREGULATION; WNT SIGNALING PATHWAY; ANIMAL; BREAST TUMOR; DISEASE COURSE; GENETIC TRANSCRIPTION; GENETICS; NONOBESE DIABETIC MOUSE; PAGET NIPPLE DISEASE; PATHOLOGY; SCID MOUSE; TUMOR RECURRENCE;

ANIMALS; BETA CATENIN; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRANSCRIPTION, GENETIC; TRANSCRIPTOME; UP-REGULATION; WNT PROTEINS;

EID: 84941798435     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-015-0630-z     Document Type: Article

References (50)

1. Betsill Jr WL, Rosen PP, Lieberman PH, Robbins GF. Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. JAMA. 1978;239:1863-7.
2. Nielsen M, Jensen J, Andersen J. Precancerous and cancerous breast lesions during lifetime and at autopsy. A study of 83 women. Cancer. 1984;54:612-5.
3. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004;96:906-20.
4. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA. 2003;100:5974-9. doi: 10.1073/pnas.09312611000931261100 .
5. Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res. 2003;1:362-75.
6. Yao J, Weremowicz S, Feng B, Gentleman RC, Marks JR, Gelman R, et al. Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res. 2006;66:4065-78.
7. Liao S, Desouki MM, Gaile DP, Shepherd L, Nowak NJ, Conroy J, et al. Differential copy number aberrations in novel candidate genes associated with progression from in situ to invasive ductal carcinoma of the breast. Genes Chromosomes Cancer. 2012;51:1067-78. doi: 10.1002/gcc.21991 .
8. Hernandez L, Wilkerson PM, Lambros MB, Campion-Flora A, Rodrigues DN, Gauthier A, et al. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J Pathol. 2012;227:42-52. doi: 10.1002/path.3990 .
9. Behbod F, Kittrell FS, LaMarca H, Edwards D, Kerbawy S, Heestand JC, et al. An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res. 2009;11:R66.
10. de la Roche M, Worm J, Bienz M. The function of BCL9 in Wnt/beta-catenin signaling and colorectal cancer cells. BMC Cancer. 2008;8:199. doi: 10.1186/1471-2407-8-199 .
11. Mani M, Carrasco DE, Zhang Y, Takada K, Gatt ME, Dutta-Simmons J, et al. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res. 2009;69:7577-86. doi: 10.1158/0008-5472.CAN-09-0773 .
12. Barnabas N, Cohen D. Phenotypic and molecular characterization of MCF10DCIS and SUM breast cancer cell lines. Int J Breast Cancer. 2013;2013:872743. doi: 10.1155/2013/872743 .
13. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet. 1995;345(8958):1154-7.
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-8. doi: 10.1006/meth.2001.1262 .
15. Cluster manual. http://bonsai.hgc.jp/~mdehoon/software/cluster/cluster3.pdf .
16. Cluster software download. http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm#ctv .
17. http://statweb.stanford.edu/~tibs/SAM .
18. SAM software download. www.qiagen.com/ingenuity .
19. Ingenuity Pathway analysis IPA. http://www.ingenuity.com .
20. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65890 .
21. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008;5:621-8. doi: 10.1038/nmeth.1226 .
22. Robinson MD, Smyth GK. Small-sample estimation of negative binomial dispersion, with applications to SAGE data. Biostatistics. 2008;9:321-32. doi: 10.1093/biostatistics/kxm030 .
23. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66301 .
24. The Cancer Genome Atlas (TCGA) data portal. http://cancergenome.nih.gov/ .
25. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139-40. doi: 10.1093/bioinformatics/btp616 .
26. McCarthy DJ, Chen Y, Smyth GK. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res. 2012;40:4288-97. doi: 10.1093/nar/gks042 .
27. Valdez KE, Fan F, Smith W, Allred DC, Medina D, Behbod F. Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model. J Pathol. 2011;225:565-73. doi: 10.1002/path.2969 .
28. http://imagej.nih.gov/ij/ .
29. Veeman MT, Slusarski DC, Kaykas A, Louie SH, Moon RT. Zebrafish prickle, a modulator of noncanonical Wnt/Fz signaling, regulates gastrulation movements. Curr Biol. 2003;13:680-5.
30. Kolligs FT, Hu G, Dang CV, Fearon ER. Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol Cell Biol. 1999;19:5696-706.
31. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA. 2003;9:493-501.
32. Elsarraj HS, Hong Y, Valdez K, Carletti M, Salah SM, Raimo M, et al. A novel role of microRNA146b in promoting mammary alveolar progenitor cell maintenance. J Cell Sci. 2013;126:2446-58. doi: 10.1242/jcs.119214 .
33. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell. 2011;145:926-40.
34. Savagner P. The epithelial-mesenchymal transition (EMT) phenomenon. Ann Oncol. 2010;21 Suppl 7:vii89-92. doi: 10.1093/annonc/mdq292 .
35. Kramps T, Peter O, Brunner E, Nellen D, Froesch B, Chatterjee S, et al. Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell. 2002;109:47-60.
36. Toya H, Oyama T, Ohwada S, Togo N, Sakamoto I, Horiguchi J, et al. Immunohistochemical expression of the beta-catenin-interacting protein B9L is associated with histological high nuclear grade and immunohistochemical ErbB2/HER-2 expression in breast cancers. Cancer Sci. 2007;98:484-90. doi: 10.1111/j.1349-7006.2007.00430.x .
37. Zatula N, Wiese M, Bunzendahl J, Birchmeier W, Perske C, Bleckmann A, et al. The BCL9-2 proto-oncogene governs estrogen receptor alpha expression in breast tumorigenesis. Oncotarget. 2014;5:6770-87.
38. Katoh M. Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. Stem Cell Rev. 2007;3:30-8.
39. Katoh M, Katoh M. WNT antagonist, DKK2, is a Notch signaling target in intestinal stem cells: augmentation of a negative regulation system for canonical WNT signaling pathway by the Notch-DKK2 signaling loop in primates. Int J Mol Med. 2007;19:197-201.
40. Katoh M, Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res. 2007;13:4042-5. doi: 10.1158/1078-0432.CCR-06-2316 .
41. Takada K, Zhu D, Bird GH, Sukhdeo K, Zhao JJ, Mani M, et al. Targeted disruption of the BCL9/beta-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med. 2012;4:148ra17. doi: 10.1126/scitranslmed.3003808 .
42. Deka J, Wiedemann N, Anderle P, Murphy-Seiler F, Bultinck J, Eyckerman S, et al. Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas. Cancer Res. 2010;70:6619-28. doi: 10.1158/0008-5472.CAN-10-0148 .
43. Freedman GM. Risk stratification in Ductal carcinoma in situ: The role of genomic testing. Curr Oncol Rep. 2012. doi: 10.1007/s11912-012-0280-6 .
44. Lari SA, Kuerer HM. Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer. 2011;2:232-61.
45. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330-7. doi: 10.1038/nature11252 .
46. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:l1. doi: 10.1126/scisignal.2004088 .
47. Mosimann C, Hausmann G, Basler K. Beta-catenin hits chromatin: regulation of Wnt target gene activation. Nat Rev Mol Cell Biol. 2009;10:276-86. doi: 10.1038/nrm2654 .
48. Orsetti B, Nugoli M, Cervera N, Lasorsa L, Chuchana P, Rouge C, et al. Genetic profiling of chromosome 1 in breast cancer: mapping of regions of gains and losses and identification of candidate genes on 1q. Br J Cancer. 2006;95:1439-47. doi: 10.1038/sj.bjc.6603433 .
49. Fiedler M, Sanchez-Barrena MJ, Nekrasov M, Mieszczanek J, Rybin V, Muller J, et al. Decoding of methylated histone H3 tail by the Pygo-BCL9 Wnt signaling complex. Mol Cell. 2008;30:507-18. doi: 10.1016/j.molcel.2008.03.011 .
50. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70. doi: 10.1038/nature11412 .